Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2008 by University of Texas Southwestern Medical Center.
Recruitment status was  Not yet recruiting
Information provided by:
University of Texas Southwestern Medical Center Identifier:
First received: August 29, 2008
Last updated: NA
Last verified: June 2008
History: No changes posted

This is a randomized prospective trial which addresses the question of whether use of an oral hypoglycemic agent as an adjunct to diet therapy in women with mild gestational diabetes will result in achieving euglycemia in a shorter period of time and, in turn, result in less frequent maternal and neonatal morbidities. This study is designed to test the hypothesis that in women with mild GDM, use of Glyburide in addition to diet and nutritional counseling lowers mean infant birth weight by 200 grams as compared with diet and nutritional counseling alone.

Condition Intervention Phase
Mild Gestational Diabetes
Drug: Glyburide
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Clinical Trial of Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo

Resource links provided by NLM:

Further study details as provided by University of Texas Southwestern Medical Center:

Primary Outcome Measures:
  • Fetal weight reduction of 200gm with Glyburide treatment [ Time Frame: Immediately after delivery of fetus ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Large for gestational age infants [ Time Frame: After delivery ] [ Designated as safety issue: No ]
  • Macrosomia [ Time Frame: After delivery ] [ Designated as safety issue: No ]
  • Neonatal Intensive Care Unit admissions [ Time Frame: Until hospital discharge ] [ Designated as safety issue: No ]
  • Rate of cesarean delivery [ Time Frame: After delivery ] [ Designated as safety issue: No ]
  • Risk of preeclampsia [ Time Frame: until hospital discharge ] [ Designated as safety issue: No ]
  • Time to achieve glycemic control [ Time Frame: after delivery ] [ Designated as safety issue: No ]
  • Need for insulin treatment [ Time Frame: after delivery ] [ Designated as safety issue: No ]

Estimated Enrollment: 400
Study Start Date: August 2008
Estimated Study Completion Date: June 2010
Estimated Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
Drug: Glyburide
Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.
Placebo Comparator: 2
Women with mild gestational diabetes will be started ADA diet and placebo.
Drug: Placebo
Sham dose adjustments of the placebo will be made.


Ages Eligible for Study:   16 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • A glucose value of ≥140 mg/dl on a 50-gram oral glucose loading test by plasma at gestational age between 24 weeks 0 days and 27 weeks 6 days based on clinical information
  • An Abnormal 3-hour oral glucose tolerance test with a fasting glucose of ≤105 mg/dl
  • Gestational age of less than or equal to 28 weeks and 0 days at the time of consent/randomization
  • Singleton gestation

Exclusion Criteria:

  • Established pregestational diabetes
  • Abnormal gestational diabetes testing (≥140) prior to 24 weeks 0 days of gestation. Women who have a negative glucose loading test (<140mg/dl) before 24 weeks may still be considered for this study if they present again for glucose tolerance testing between 24 and 27 weeks.
  • Multiple gestations
  • Known major fetal anomaly or fetal demise
  • Any renal disease with serum creatinine of >1.0
  • Known liver disease such as hepatitis
  • Maternal or fetal conditions likely to require imminent or very preterm delivery such as preeclampsia, preterm premature rupture of the membranes, preterm labor, and intrauterine fetal growth restriction
  • Known hypersensitivity or allergic reaction to Glyburide
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00744965

Contact: Mina Abbassi-Ghanavati, MD 214-648-2646
Contact: Kenneth J Leveno, MD 214-648-2316

United States, Texas
Parkland Memorial Hospital Not yet recruiting
Dallas, Texas, United States, 75235
Contact: Mina Abbassi-Ghanavati, MD    214-648-2646   
Principal Investigator: Mina Abbassi-Ghanavati, MD         
Sponsors and Collaborators
University of Texas Southwestern Medical Center
  More Information

No publications provided

Responsible Party: Mina Abbassi-Ghanavati, UT Southwestern Medical Center Identifier: NCT00744965     History of Changes
Other Study ID Numbers: 042008-058
Study First Received: August 29, 2008
Last Updated: August 29, 2008
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes, Gestational
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Pregnancy Complications
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs processed this record on November 25, 2014